Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion has entered into a global license-in agreement worth up to USD 744.0M (approx. KRW 1.06T) with US-based Kaigene, Inc. for two novel drug candidates targeting rare autoimmune diseases.
📊 [Key Disclosure Details & Financial Summary]
- Disclosure Title: Execution of License-in Agreement for Novel Drug Candidates for Rare Autoimmune Diseases (Major Management Matters)
- Counterparty: Kaigene, Inc. (USA)
- Contract / Confirmation Date: November 4, 2025
- Contract Subject & Rights Scope:
- FcRn Inhibitor: Global rights (excluding Japan, China, Taiwan, Hong Kong, and Macao)
- Specific Autoantibody Degrader: Worldwide global rights
- Contract Period: From execution date until the latest of ① substance patent expiration, ② 12 years from first commercial sale, or ③ expiration of regulatory exclusivity per country
- Contract Values (Applied Exchange Rate: Basic rate on 2025-11-04 USD/KRW 1,427.40):
- Total Contract Value: Up to USD 744,000,000 (approx. KRW 1.062T)
- Upfront Fee: USD 8,000,000 (approx. KRW 11.4B)
- Development Milestones: Up to USD 111,000,000 (approx. KRW 158.4B / including up to $11M through Phase 1 initiation, payable upon clinical and regulatory milestones)
- Sales Milestones: Up to USD 625,000,000 (approx. KRW 892.1B / based on commercial sales benchmarks, assuming $4.0B in net sales)
- Royalties: Tiered running royalties of 5% to 10% on net sales
- Investment Caution & Risk Factors:
- The contract may be terminated in case of research/development suspension by regulatory authorities or failure in product approval
- Development/sales milestones and royalties are conditional upon achieving specific targets and may not be fully paid (no penalty fees incurred if terminated early)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Phase 1 Clinical Entry and Development Milestone Execution
This disclosure details Celltrion’s license-in agreement with Kaigene for two novel drug candidates to strengthen its autoimmune pipeline, making it important to monitor entry into Phase 1 clinical trials and subsequent development milestone executions. Tracking clinical trial progress following technology integration ensures verification of R&D execution. Clinical trial advances, milestone payments, and key R&D updates can be verified through future regulatory disclosures or upcoming periodic filings (Quarterly, Half-Yearly, or Annual Business Reports).
📢 Disclaimer & Source Information
Source: This content was newly generated and structured based on official data submitted to the Data Analysis, Retrieval and Transfer System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
